Objective: To characterize the interactive effects of amylin with phentermine or sibutramine on food intake, body weight/ composition and gene expression in diet-induced obese (DIO) rats. Design: DIO rats were intraperitoneally injected with a single dose of amylin (10 mg kg À1 ) and/or phentermine (1 mg kg À1 ) or chronically infused with amylin (100 mg kg À1 d À1 ) or vehicle with or without phentermine (0.5-10 mg kg À1 d À1 ) or sibutramine (3 mg kg À1 d À1 ) using two surgically implanted subcutaneous osmotic mini-pumps. Measurements: Twenty-four hour food intake, locomotor activity and components of meal microstructure (meal size, latency, duration and intermeal interval) were measured following acute administration (amylin, phentermine or amylin þ phentermine). Body weight and composition (for amylin and/or sibutramine or phentermine) and metabolism-related gene mRNA expression in the liver (fatty acid synthase, stearoyl-CoA desaturase-1 and carnitine palmitoyltransferase-1) and brown fat (b-adrenergic receptors and uncoupling protein-1) were measured (for amylin and/or phentermine) after sustained infusion (2 weeks). Results: Acute co-administration of amylin (10 mg kg À1 ) and phentermine (1 mg kg À1 ) reduced acute food intake (up to 19 h) more than either monotherapy. In two studies, sustained subcutaneous infusion of amylin for 2 weeks decreased cumulative food intake (22%) and vehicle-corrected body weight gain (B4-8%). Phentermine's anorexigenic (10-17%) and weightreducing effects (B0-5%) were only evident at the highest dose tested (10 mg kg À1 d À1 ). Combination of amylin (100 mg kg À1 d À1 ) and phentermine reduced food intake (30-43%), body weight (8-12%) and adiposity to a greater extent than either monotherapy. Amylin prevented phentermine-induced reductions in UCP-1 mRNA in brown adipose tissue. When amylin þ sibutramine were infused, mathematically additive decreases in food intake (up to 45%) and body weight (up to 12%) were evident. Similar to amylin þ phentermine treatment, amylin þ sibutramine mediated weight loss was attributable to significant reductions in fat mass. Conclusions: Combined treatment of DIO rats with the pancreatic b-cell hormone amylin and phentermine or sibutramine resulted in additive anorexigenic, weight-and fat-reducing effects.
Introduction
Energy homeostasis is regulated by a complex interplay between multiple peptide hormones, which originate from peripheral sources such as adipocytes, the pancreas and the gut and converge in the brain. These peripherally derived hormones can act as long-term signals of energy stores or as short-term signals of hunger, satiety and satiation, and are coordinated within central sites to regulate feeding behavior, metabolism and, ultimately, body weight. 1, 2 Amylin is co-secreted from pancreatic b-cells with insulin in response to nutrient ingestion. In rodents, acute administration of amylin reduced meal size. 3, 4 Chronic peripheral infusion of amylin to lean or diet-induced obese (DIO) rats decreased food intake and body weight. [5] [6] [7] [8] [9] These preclinical findings concerning the antiobesity effects of amylin agonism have been confirmed in various clinical studies. Pramlintide, a synthetic analog of human amylin, has been shown in obese subjects to reduce single meal and 24-h food intake. 10, 11 With longer term administration, pramlintide treatment induced placebo-corrected weight loss of 3.7% over 16 weeks, and up to 6.8% at 1 year. 10 The most common adverse event in these trials was nausea, which was primarily mild to moderate and transient in nature. 12, 13 Phentermine and sibutramine are two monoaminergic antiobesity agents indicated for the short-and long-term management of obesity, respectively. Phentermine is a b-phenethylaminic derivative that acts through monoaminergic systems (noradrenaline and dopamine) to decrease food intake and body weight. Rodent models suggest that phentermine causes weight loss via effects on caloric intake and metabolic rate.
14 Sibutramine inhibits the reuptake of central noradrenaline and serotonin and stimulates thermogenesis in rodents. 15, 16 Depending upon the trial design, clinical studies have revealed that both agents elicit statistically significant weight loss ranging from 4-8% (placebo-corrected). 7, 17 Although monotherapy treatment in clinical studies with various anorexigenic agents, whether small molecules or peptide hormone therapeutics, can significantly reduce weight, the overall magnitude of weight loss tends to be modest, plateauing in the single-digit range. 18 These modest effects have been attributed, in part, to the redundancy of feeding pathways. Combining agents with different anorexigenic mechanisms, such as a small molecule and a peptide hormone, may help mitigate some of the redundancies and facilitate additive reductions in food intake and body weight. The primary mechanisms mediating the antiobesity properties of phentermine or sibutramine (re-uptake/release of classic neurotransmitters) appear to differ from amylin's (activation of hindbrain amylin receptors). However, the a priori assumption that their combined administration will elicit additive anorexigenic and weight reducing effects may not be necessarily correct. For example, if amylin were just upstream of these neurotransmitter systems, additive effects would not necessarily be expected. To test this, we examined the individual and combined effects of these agents on changes in food intake, body weight and adiposity in DIO rats, an accepted surrogate model of human obesity. 19 
Materials and methods
Animals, drugs and drug administration All studies were approved by the Institutional Animal Care and Use Committee at Amylin Pharmaceuticals, Inc. in accordance with Animal Welfare Act guidelines. Animals were housed individually in standard caging at 22 1C in a 12-h light and 12-h dark cycle. Acute studies (meal pattern analyses and locomotor activity) used male Harlan SpragueDawley rats (Harlan, Indianapolis, IN, USA) maintained on a moderately high-fat diet (32% kcal from fat; D12266B, Research Diets, New Brunswick, NJ, USA). Sustained infusion studies were conducted using in-bred male DIO-prone 19 male rats (Charles Rivers Labs, Wilmington, MA, USA) that were fattened for 6 weeks on a moderately high-fat diet (32% kcal from fat; Research Diets no. D12266B) and maintained ad libitum on this diet during testing. For acute injection studies, rat amylin (Peptisyntha, Torrance, CA, USA) was dissolved in 10% dimethylsulfoxide (DMSO) in sterile water. For studies using osmotic minipumps, rat amylin was dissolved in 50% DMSO in sterile water. Mini-pump administration of 50% DMSO has no discernible effect on food intake or body weight gain as compared to sterile water (unpublished observations). Sibutramine was extracted from the drug product Meridia (Abbott Laboratories, IL, USA) using water as a solvent, purified by RP-HPLC (reverse phase-high performance liquid chromatography (498% purity)) and characterized by NMR and LC/MS. Phentermine (Sigma-Aldrich, St Louis, MO, USA) and sibutramine were dissolved in sterile water for acute injection and mini-pump administration.
24-h food intake monitoring and meal pattern analysis
Harlan Sprague-Dawley rats were habituated to the testing chamber, food hopper and diet for 10 days prior to the study. Testing chambers (10.5 Â 19 Â 8 inches; BioDAQ Food Intake Monitoring System, Research Diets) were equipped with a tunnel containing a food hopper at the end. Rats received daily intraperitoneal (i.p.) injections of vehicle (10% DMSO in sterile water) prior to lights off on days 8, 9 and 10 of habituation. Following habituation, rats were divided into treatment groups (7-8 rats/group) of equal food consumption.
On the test day, rats with a mean body weight of 411±5.7 g received a single i.p. injection of amylin (10 mg kg À1 ) or vehicle (10% DMSO in sterile water) and a single i.p. injection of either phentermine (1 mg kg À1 ) or vehicle (sterile water) 15 min prior to onset of the dark cycle and were placed immediately back into the BioDAQ Food Intake Monitor cages. These doses of amylin and phentermine were selected to only modestly and transiently suppress food intake when given alone and to allow ample dynamic range to see additional effects when given in combination. 3, 20 Food hoppers were weighed automatically every 5 s throughout the experiment. Cumulative food intake was monitored for 24 h. Latency, meal size, intermeal interval and satiety ratio (the intermeal interval/meal size) were analyzed for the first meal as described previously. 3 Minimum meal size was set at 0.2 g with an intermeal interval of X15 min.
Chronic administration
Using aseptic technique, rats were surgically implanted with two osmotic subcutaneous mini-pumps (Durect Corp, Cupertino, CA, USA). In all experiments, rat amylin was infused at a rate of 100 mg kg
). In the first experiment, rats (initial weight 455 ± 6 g) were continuously infused with rat amylin or vehicle (50% DMSO in sterile water) and either phentermine Co-administration of amylin and phentermine JD Roth et al
) or vehicle (sterile water) for 2 weeks (n ¼ 6 per group). In the dose-dependency experiment, rats (initial weight 495 ± 4 g) were infused with rat amylin or vehicle (50% DMSO in sterile water) and either phentermine (0.5, 1, 2.5, 5 and 10 mg kg À1 d
À1
) or vehicle (sterile water) for 2 weeks (n ¼ 5 per group). In a separate experiment, rats (n ¼ 5 per group) were infused with rat amylin or vehicle (50% DMSO in sterile water) and either sibutramine (3 mg kg À1 d
) or vehicle (sterile water). Body weight and cumulative food intake were measured weekly for 2 weeks.
Locomotor activity
Rats were placed into individual cages within SmartFrame Cage Racks (Kinder Scientific, San Diego, CA, USA) with ad libitum access to food and water, and were undisturbed for 24 h. Locomotor activity was assessed over a 24 h period from the morning of day 5 to the morning of day 6 using a MotorMonitor system (Hamilton Kinder, Julian, CA, USA). MotorMonitor software (Kinder Scientific) was used to analyze the data. Data is expressed as total distance traveled (inches) stratified into light and dark phase activity.
Body composition
Rats were briefly placed (B1 min) in a ventilated plexiglass tube that was then inserted into a rodent NMR machine (Echo Medical Systems, Houston, TX, USA). Rats were scanned prior to pump implantation and on the final day of the experiment (after removal of the mini-pumps) and changes in fat mass and dry lean tissue were calculated as described previously. 9 
Plasma parameters
Following an overnight fast, terminal cardiac blood was collected after isoflurane inhalation on day 14 and plasma amylin, and leptin levels were measured using a LINCOplex Multiplex assay (Millipore, Billerica, MA, USA).
Gene expression
Liver, and brown adipose tissue were removed at termination and immediately snap frozen in liquid nitrogen and stored at À801 C. Total RNA was extracted using TRIreagent per manufacturer's directions (Ambion, Austin, TX, USA). Quantitative real time PCR for target genes was performed using Taqman gene expression assays-on-demand and TaqMan One-Step RT-PCR Master Mix Reagents (Applied Biosystems, Foster City, CA, USA) on an ABI PRISM 7900 Sequence Detection System (Applied Biosystems).
Data analyses
Comparisons between treatment groups were performed using one-way analysis of variance followed by contrasts. Adjustments for multiple comparisons were not performed due to the small sample size. An outlying data point was excluded if its studentized residual was more than three s.d. from the mean. Statistical analyses were done in SAS version 8.2 (SAS Institute, Inc., Cary, NC, USA) or Prism 4 for Windows (GraphPad Software, San Diego, CA, USA). Graphs were generated using Prism 4 for Windows (Graphpad Software). Data are presented as mean±s.e. For all analyses, the significance level was 0.05.
Results
Acute administration of amylin and phentermine Consistent with previous reports, 3, 4 amylin decreased the size of the first meal consumed after administration (Table 1 ; Po0.05 vs vehicle). Phentermine did not significantly affect meal size, latency, duration or the satiety ratio (calculated as the intermeal interval divided by the meal size). Combined administration of amylin þ phentermine significantly increased latency (time to the first meal) and satiety ratio (Po0.05 vs vehicle). Despite this increase in latency, the meals were of a similar size and duration (Table 1) . Food consumption over a 24-h period increased progressively throughout the dark cycle and diminished during the light cycle (Figure 1 ). At 1-h, administration of either amylin or phentermine significantly reduced cumulative food intake (Po0.05 vs vehicle). The combination of amylin þ phentermine continued to suppress food intake for 19 h postinjection (Po0.05 vs vehicle).
At the doses tested in the present study, amylin did not alter locomotor activity, whereas phentermine significantly Co-administration of amylin and phentermine JD Roth et al increased locomotor activity 2-h and 3-h post-injection (data not shown), and total locomotor activity during the dark cycle (Table 1 ; Po0.05 vs vehicle and amylin). Locomotor behaviors were not further increased by amylin þ phentermine relative to phentermine alone (Po0.05 vs vehicle).
Chronic administration of amylin and phentermine in DIO rats
The finding that acute administration of amylin þ phentermine was anorexigenic 19 h after administration led us to test the durability and potential weight-reducing effects of the combination using continuous drug administration. Following 2 weeks of treatment, amylin induced significant body weight loss compared to vehicle controls. Whereas phentermine, at the dose tested, tended to insignificantly reduce body weight throughout the study, the combination of amylin þ phentermine reduced body weight to a significantly greater extent compared to amylin administration alone (Figure 2a ). Cumulative food intake (over 2 weeks) was significantly reduced by amylin (20.6 ± 3.3%, Po0.05 vs vehicle) and tended to be reduced by phentermine (9.5±4.3%, NS from vehicle). Combination treatment with amylin þ phentermine reduced cumulative food intake by 29.8 ± 2.6% (Po0.05 vs vehicle and monotherapies), in a mathematically additive manner. Weight loss with amylin and amylin þ phentermine was most evident during the first week of treatment and stabilized between weeks 1 and 2. Food intake was significantly reduced by amylin and amylin þ phentermine at weeks 1 and 2. Amylin and amylin þ phentermine-treated animals never consumed more food relative to vehicle controls, implying that the anorexigenic effects of these agents were still evident with sustained administration and had reached an appropriate level to sustain their new body weight. Reductions in fat mass were evident with amylin, but not phentermine treatment, compared to vehicle controls ( Figure 2c ). The combination of amylin and phentermine reduced fat mass to a greater extent than amylin monotherapy (Figure 2c ; Po0.05). To correct for changes in fat mass expected with weight loss, we also calculated adiposity (fat mass as a percent of body weight). Adiposity was significantly reduced by amylin and phentermine combination treatment compared to amylin monotherapy (change in percent fat mass from baseline: vehicle À1.5±0.9%, amylin À4.7±0.5%, phentermine À3.0 ± 0.6%, amylin þ phentermine À6.9 ± 0.7%; Po0.05 for amylin vs vehicle, amylin þ phentermine vs vehicle and amylin þ phentermine vs amylin). Weight and fat loss were not associated with significant changes in lean mass in any of the treatment groups (Figure 2d ).
Plasma parameters
Consistent with previous studies, 9 DIO-prone vehicle-treated rats were hyperleptinemic (18.8 ± 1.9 ng ml
À1
). In line with the observed changes in body adiposity, leptin levels were unchanged by phentermine alone (17.9 ± 2.0 ng ml À1 ), but were significantly reduced by amylin (10.1 ± 1.6 ng ml
) and amylin þ phentermine (8.6±0.9 ng ml À1 ; both Po0.05 vs vehicle). With amylin treatment, amylin levels were elevated to a similar extent in amylin (288 ± 62 pM) and amylin þ phentermine-treated rats (288±52 pM) compared to vehicle (7.0±1.0 pM) and phentemine treated rats (21±11 pM).
Effects of amylin, phentermine and amylin þ phentermine on peripheral gene expression profiles One possible mechanism for the observed additivity of amylin and phentermine effects could be amylin enhancing phentermine-induced activation of catecholaminergic Co-administration of amylin and phentermine JD Roth et al systems.
To investigate this hypothesis, we measured gene expression changes of b-adrenergic receptors (Adrb1-3) and uncoupling protein-1 (UCP-1), a marker of thermogenesis, in brown adipose. Adrb1 and Adrb3 mRNA levels were unchanged irrespective of treatment (Figures 3b and d) . Sustained administration of phentermine was associated with decreased mRNA levels of Adrb2 and UCP-1 ( Figures  3a and c) . Amylin infusion was also associated with decreased Adrb2 expression, but was not associated with decreased UCP-1 mRNA expression as was previously observed. 9 Combined administration of amylin þ phentermine tended to further reduce mRNA levels of Adrb2 (Figure 3c ). However, despite amylin þ phentermine-treated rats losing twice as much body weight as amylin-treated rats, mRNA levels of UCP-1 were unchanged relative to vehicle controls (Figure 3a) . The hepatic metabolic markers fatty acid synthase, stearoyl-CoA desaturase-1 (Scd1), sterol regulatory elementbinding protein-1 and -2 (Srebp1 and Srebp1) and acetyl-CoA carboxylase-1 and -2 (Acc1 and Acc2) were unaffected by treatment, indicating no effect of amylin and phentermine administration on hepatic lipogenesis (data not shown). The expression of the liver isoform of carnitine palmitoyltransferase-1 (Cpt1) gene, however, was modestly, but significantly, increased by phentermine treatment alone compared to all other groups (vehicle 1.0±0.2, amylin 0.7±0.1, phentermine 1.68±0.3, amylin þ phentermine 0.9±0.2; Po0.05 for phentermine vs vehicle, amylin and amylin þ phentermine groups).
Dose dependency of effects of amylin and phentermine in DIO rats
Our single dose combination study pointed to at least an additive relationship between amylin and phentermine. To test whether amylin would interact with even lower doses of phentermine, another group of rats was continuously infused with phentermine (0.5, 1.0, 2.5, 5.0 and 10.0 mg kg À1 d
À1
) with or without amylin (100 mg kg À1 d À1 ) for 2 weeks. Amylin significantly reduced cumulative food intake by 22% and body weight by 8% after 2 weeks (Table 2 ; Po0.05 vs vehicle). Although phentermine monotherapy elicited significant reductions in food intake (17%) and body weight (5%) at the highest dose tested (10.0 mg kg À1 d
; Po0.05 vs vehicle), phentermine monotherapy was largely ineffective at lower doses. Greater anorexigenic effects were observed when several of the doses of phentermine (2.5, 5.0, and 10.0 mg kg À1 d
) were combined with amylin compared to monotherapies, with up to a 42% reduction of food intake observed at the highest dose combination (Table 2) . Although all of the doses of amylin þ phentermine elicited significant weight loss compared to vehicle, the changes in food intake translated into a significant, additional change in body weight only when the highest dose of phentermine was combined with amylin (Po0.05 vs monotherapies).
Phentermine monotherapy did not reduce body fat or increase lean tissue at any of the doses tested. As observed in the previous study, the combined administration of 10 mg kg À1 d À1 of phentermine with amylin induced Co-administration of amylin and phentermine JD Roth et al fat loss significantly greater than amylin alone (data not shown; Po0.05 vs both monotherapies) without decreasing lean tissue. No changes in body composition beyond those obtained by amylin alone were evident with any of the other dose combinations (data not shown).
Co-administration of amylin and sibutramine
To extend these findings to other agents of a similar neurotransmitter class currently used to treat obesity, amylin (100 mg kg À1 d
À1
) and/or sibutramine (3 mg kg À1 d
; an anorexigenic dose selected based on published studies) 21 were continuously administered to DIO-prone rats for 2 weeks. Consistent with previous published studies, monotherapy treatment with these doses of amylin 3 or sibutramine 21 resulted in a similar, sustained reduction in cumulative food intake (25%; Po0.05 vs vehicle) and a 6-7% reduction in vehicle-corrected body weight (Po0.05 vs vehicle). The combination of amylin þ sibutramine significantly reduced cumulative food intake by 45% (Po0.05 vs vehicle and monotherapies) and body weight by 12% in a manner that was mathematically additive (Figure 4 ). Body composition analyses revealed that weight loss induced by either amylin or sibutramine monotherapy was accompanied by a significant reduction in body fat (Po0.05 vs vehicle) with a relative preservation of lean mass. Combination therapy induced an even greater decrease in body fat (Po0.05 vs vehicle and monotherapies) and was likewise lean-sparing (Figures 3c and d) . Adiposity was lower in amylin-treated (14.7±1.0%) and sibutramine-treated rats (13.7 ± 0.7%) compared to vehicle-treated rats (17.8 ± 1.1%), and rats treated with the combination of amylin þ sibutramine experienced a further reduction in adiposity to 8.8 ± 1.2% (Po0.05 vs all groups). Co-administration of amylin and phentermine JD Roth et al
Discussion
Our preclinical experiments support an additive relationship between amylin and two small molecule antiobesity agents.
Specifically, these combination studies demonstrated that:
(1) following a single acute injection the combination of amylin þ phentermine elicited a more durable reduction in food intake compared to either agent alone, (2) amylin þ phentermine, but not the monotherapies, increased the latency to eating initiation but did not produce any additional increases in locomotor activity beyond that observed with phentermine alone, (3) with sustained administration of amylin þ phentermine, or amylin þ sibutramine, cumulative food intake, body weight and adiposity were reduced in a mathematically additive manner. Several groups have described the acute anorexigenic effects and analysis of meal microstructure following a peripheral injection of amylin. 3, 4 In line with these findings, amylin's anorexigenic effects in the present studies were most evident shortly after injection, followed by a rebound in food intake most likely due to the relatively short half-life (B13 min) 22, 23 and/or compensatory responses related to negative energy balance. Analyses of meal microstructure revealed that amylin primarily reduced food intake by decreasing meal size. Consistent among reports of amylin on feeding microstructure is the finding that meal size is virtually always reduced, and this effect occurs at lower doses than the effects on other feeding variables. 3, [24] [25] [26] In the present study, amylin also tended to increase meal latency, however, this effect did not achieve statistical significance.
The effects of phentermine on meal patterns in rodents have not been well characterized in the published literature; however, in baboons, phentermine was associated with an increase in latency to the first meal. 27 The dose of phentermine tested here did not meaningfully change meal patterns. The combined administration of amylin and phentermine elicited effects on the components of meal microstructure that were not expected. Amylin and phentermine mediated decreases in food intake were not attributable to a greater decrease in meal size (as was seen with amylin alone), but appeared attributable, rather, to a greater than twofold increase in latency to eat. Furthermore, despite consuming meals of similar size, amylin þ phentermine administration was associated with a prolonged intermeal interval compared to vehicle controls. These dual effects on latency and increased intermeal interval not only demonstrate the value of combinatorial regimens, but may also point to potential mechanisms. One possible explanation for the increase in latency to eat could be amylin-mediated increases in the anorexigenic catecholaminergic systems activated by phentermine. Increases in tryptophan transport, hypothalamic tryptophan and the 5-HT metabolite 5-HIAA have been reported following central or peripheral amylin administration. [28] [29] [30] Intermeal interval is governed by a complex Co-administration of amylin and phentermine JD Roth et al neurohormonal signals is unknown, but could contribute to amylin þ phentermine protraction of the intermeal interval. The generation of plasma hormonal profiles in amylin þ phentermine-treated rats before and after the consumption of a meal, and/or the assessment of food intake in the context of a sham feeding preparation may aid in our understanding of these potential mechanisms. 33 Consistent with previous reports in rodents, locomotor activity was unaffected by amylin administration, 34 whereas phentermine was associated with increased physical activity. 3, 20, 35 The observation that locomotor behaviors were not further increased by amylin þ phentermine relative to phentermine alone suggests that the increased anorexigenic effects of the combination were not mediated by the amplification of competing locomotor behaviors. The increases in locomotor activity following phentermine administration and associated increases in energy expenditure may have contributed to the enhanced weight loss seen with amylin þ phentermine combination treatment. Indeed, phentermine has been reported to induce an increase in energy expenditure in obese mice. 36 Whether increases in metabolic rate or fat utilization occurred following combination treatment with amylin þ phentermine administration is unknown and would require further experimentation using indirect calorimetry techniques. Nevertheless, it is noteworthy that amylin and phentermine interacted to exert additive anorexigenic effects without further increasing locomotor activity.
Having established an additive effect of amylin and phentermine on short-term food intake, we next examined whether chronic treatment would elicit additive, durable weight loss. In DIO rats, the dose of amylin selected reduced body weight by 4-6% over a 2 week period, consistent with previous reports. 3, 9 Although phentermine (0-5 mg kg
À1
) has been shown to decrease acute food intake in various rodent models following a single injection, the present findings are consistent with other reports showing little (o3%) or no change in body weight with sustained administration of phentermine (5 mg ) augmented amylin's anorexigenic effects, inducing up to a 30% reduction in food intake. The highest dose of phentermine (10 mg kg À1 d
) enhanced amylin's actions on food intake and body weight resulting in a 40 and 12% reduction, respectively, significantly greater effects than that achieved with either agent alone. Body composition analyses indicated that weight loss with amylin, or amylin and phentermine combination, was fat-specific, and not accompanied by loss of lean tissue. Although a formal pharmacological demonstration of additivity or synergy would require more sophisticated experimental designs such as isobolographic or response surface methodology, 32, 37 these findings provide preclinical proof-of-concept for a mathematically additive interaction between phentermine and amylin for anorexigenic effects and weight loss within certain dose ranges.
Several of the observed changes in gene expression shed light on potential mechanisms mediating the additive weight-and fat-lowering effects of amylin and phentermine. In contrast to phentermine monotherapy, sustained administration of amylin resulted in significant weight and fat loss. As a catecholaminergic, it is not surprising that phentermine was associated with decreased mRNA levels of Adrb2. However, the accompanying downregulation in brown adipose UCP-1 mRNA (a marker of thermogenesis) suggests one compensatory mechanism engaged against phentermine's effects on body weight. A second novel finding was that amylin was also associated with Adrb2 downregulation in brown adipose tissue. These effects were likely indirect, as amylin has no known direct effects on brown adipose, 38 and could reflect a compensatory response to negative energy balance. Amylin-mediated weight loss was not associated with decreased mRNA levels of UCP-1 in brown fat, consistent with our previous observations that DIO-prone rats maintain energy expenditure levels in the face of amylin-induced weight loss. 3, 9 Additionally, when amylin was co-administered with phentermine, the compensatory decrease in UCP-1 mRNA was prevented. Phentermine, but not amylin þ phentermine, significantly increased hepatic levels of CPT-1 mRNA. These results suggest a phenterminemediated induction in hepatic fatty acid oxidation that is no longer evident in combination treated animals. Further investigation of mitochondrial and oxidative target genes would be required to confirm a role for phentermine in hepatic lipid oxidation. We acknowledge that there are caveats with relying on gene expression as a proxy for protein levels, and that, furthermore, these studies did not include a pair-fed control group, so the overall contribution of caloric restriction alone remains to be elucidated. Additive anorexigenic, weight and fat-lowering effects were also evident following the combined administration of amylin and sibutramine. Sibutramine, a serotonin noradrenaline reuptake inhibitor (SNRI), acts by inhibiting the re-uptake of the catecholamines serotonin and noradrenaline. In contrast, phentermine does not inhibit monoamine reuptake, but instead promotes the release of noradrenaline, serotonin and dopamine from pre-sysnaptic stores. Thus, amylin may interact in an additive manner with the monoaminergic class of antiobesity agents in general, irrespective of their mechanism of action (that is, re-uptake, inhibition or releasing agents). Interestingly, weight loss in amylin-treated rats and pair-fed controls is accompanied by a similar increase in arcuate neuropeptide Y mRNA levels, 9 whereas sibutramine has been shown to blunt this increase. 39 Future mechanistic studies should also encompass the contribution of the complementary mechanisms of action of amylin and phentermine/sibutramine on classic neurotransmitter as well as hypothalamic neuropeptides known to regulate energy homeostasis. The present studies extend emerging literature, where additive or synergistic interactions are reported for amylin in 32 and leptin), 40, 41 to include small molecule agents that act via classic neurotransmitters. Consistent with the results reported here, co-administration of the amylin agonist pramlintide with sibutramine or phentermine in a clinical trial has recently been reported to result in increased weight loss in obese subjects. 42 Collectively, these studies support the notion that combination therapies may help overcome the redundancies of the central nervous system feeding pathways with the potential to elicit additive weight loss.
